Relaxo Footwears Limited
Momentum (89/100) does the heavy lifting; valuation (3/100) is the drag.
ExpensiveOvervaluedRelaxo Footwears Limited earns a Hold from StocksWizard, with a blended score of 45/100. We put fair value near ₹201.98; at ₹403.95 that leaves roughly 50% downside, so the stock screens overvalued by 50%. On 51.1x trailing earnings it sits pricier than the Consumer Cyclical median of about 27.7x. The price is about 19% below its 52-week high of ₹499.4 and 70% above the low of ₹237.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹380.8 implies about 6% downside across 10 analysts. It clears 7 of 13 investability checks, with durability 54, valuation 6 and momentum 89 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹161.58.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-19.11% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 8.3%
- Pass: Low debt (D/E < 0.5): 0.11x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 8%
- Pass: Earnings growing: 21%
- Fail: Net margin ≥ 10%: 6.6%
- Pass: Current ratio > 1.5: 2.33
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 8.66
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter71.3%
- Institutions11.6%
- Public & other17.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 8.66.
Opportunities
- Earnings growing (21% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Relaxo Footwears Limited
Relaxo Footwears Limited manufactures and sells footwear for men, women, and children across India and internationally. Its product range includes casual, running, athleisure, walking, sneakers, formal, sports, school, training, and gym shoes, along with slippers, sandals, flip flops, slides, chappals, and clogs. The company operates multiple brands including Relaxo, Bahamas, Flite, Sparx, BOSTON, Mary Jane, Schoolmate, and KidsFun.
Relaxo Footwears Limited — frequently asked questions
Is Relaxo Footwears Limited a buy, hold or sell?
StocksWizard currently rates Relaxo Footwears Limited (RELAXO) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Relaxo Footwears Limited's fair value?
Our blended DCF and relative-valuation model estimates Relaxo Footwears Limited's fair value at about ₹201.98, versus a current price of ₹403.95 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Relaxo Footwears Limited financially healthy?
Relaxo Footwears Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Relaxo Footwears Limited's share price performed?
Relaxo Footwears Limited is up 35% over three months, and last traded at ₹403.95. Past performance doesn't predict future returns.
More in Consumer Cyclical
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.